Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

“I think this study changes the paradigm. In current practice, PCSK9 inhibitors are largely reserved for patients who have had a prior heart attack or stroke, but here we see a benefit of using evolocumab not only to treat patients without a history of heart attack or stroke, but without known significant atherosclerosis. It's a message to physicians and patients that we don't have to wait until someone has atherosclerosis to treat them intensively. We can—and should—be much more proactive.”